Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma

Heather Magnan; Christine M. Goodbody; Elyn Riedel; Christine A. Pratilas; Leonard H. Wexler; Alexander J. Chou

doi:10.1002/pbc.25373

Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma

Heather Magnan, Christine M. Goodbody, Elyn Riedel, Christine A. Pratilas, Leonard H. Wexler, Alexander J. Chou

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Background: Outcomes for patients with metastatic Ewing sarcoma (ES) remain poor. We investigated whether the intensification of ifosfamide improved survival for patients with metastatic ES. Procedure: We conducted a retrospective chart review of 30 patients with metastatic ES treated with the MSKCC "EFT regimen." The regimen included an intensification of ifosfamide dosing from 1,800mg/m²/day × 5 days per cycle to 2,800mg/m²/day × 5 days per cycle. Results: Twenty six of the 30 patients completed planned chemotherapy. Two patients experienced disease progression during therapy. There were no toxic deaths. One patient developed secondary leukemia. The 4-year event free survival (EFS) was 27% and the overall survival (OS) was 39%. Conclusions: Intensification of ifosfamide was tolerated and did not increase toxicity in patients with metastatic ES. The intensification did not improve outcomes for these patients with metastatic disease. Pediatr Blood Cancer 2015;62:594-597.

Original language	English (US)
Pages (from-to)	594-597
Number of pages	4
Journal	Pediatric Blood and Cancer
Volume	62
Issue number	4
DOIs	https://doi.org/10.1002/pbc.25373
State	Published - Apr 1 2015
Externally published	Yes

Keywords

Chemotherapy
Ewing sarcoma
Outcomes

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/pbc.25373

Cite this

@article{140908cecc7544bd8c7e72729f4e4e6b,

title = "Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma",

abstract = "Background: Outcomes for patients with metastatic Ewing sarcoma (ES) remain poor. We investigated whether the intensification of ifosfamide improved survival for patients with metastatic ES. Procedure: We conducted a retrospective chart review of 30 patients with metastatic ES treated with the MSKCC {"}EFT regimen.{"} The regimen included an intensification of ifosfamide dosing from 1,800mg/m2/day × 5 days per cycle to 2,800mg/m2/day × 5 days per cycle. Results: Twenty six of the 30 patients completed planned chemotherapy. Two patients experienced disease progression during therapy. There were no toxic deaths. One patient developed secondary leukemia. The 4-year event free survival (EFS) was 27% and the overall survival (OS) was 39%. Conclusions: Intensification of ifosfamide was tolerated and did not increase toxicity in patients with metastatic ES. The intensification did not improve outcomes for these patients with metastatic disease. Pediatr Blood Cancer 2015;62:594-597.",

keywords = "Chemotherapy, Ewing sarcoma, Outcomes",

author = "Heather Magnan and Goodbody, {Christine M.} and Elyn Riedel and Pratilas, {Christine A.} and Wexler, {Leonard H.} and Chou, {Alexander J.}",

note = "Publisher Copyright: {\textcopyright} 2015 Wiley Periodicals, Inc.",

year = "2015",

month = apr,

day = "1",

doi = "10.1002/pbc.25373",

language = "English (US)",

volume = "62",

pages = "594--597",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "4",

}

TY - JOUR

T1 - Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma

AU - Magnan, Heather

AU - Goodbody, Christine M.

AU - Riedel, Elyn

AU - Pratilas, Christine A.

AU - Wexler, Leonard H.

AU - Chou, Alexander J.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Background: Outcomes for patients with metastatic Ewing sarcoma (ES) remain poor. We investigated whether the intensification of ifosfamide improved survival for patients with metastatic ES. Procedure: We conducted a retrospective chart review of 30 patients with metastatic ES treated with the MSKCC "EFT regimen." The regimen included an intensification of ifosfamide dosing from 1,800mg/m2/day × 5 days per cycle to 2,800mg/m2/day × 5 days per cycle. Results: Twenty six of the 30 patients completed planned chemotherapy. Two patients experienced disease progression during therapy. There were no toxic deaths. One patient developed secondary leukemia. The 4-year event free survival (EFS) was 27% and the overall survival (OS) was 39%. Conclusions: Intensification of ifosfamide was tolerated and did not increase toxicity in patients with metastatic ES. The intensification did not improve outcomes for these patients with metastatic disease. Pediatr Blood Cancer 2015;62:594-597.

AB - Background: Outcomes for patients with metastatic Ewing sarcoma (ES) remain poor. We investigated whether the intensification of ifosfamide improved survival for patients with metastatic ES. Procedure: We conducted a retrospective chart review of 30 patients with metastatic ES treated with the MSKCC "EFT regimen." The regimen included an intensification of ifosfamide dosing from 1,800mg/m2/day × 5 days per cycle to 2,800mg/m2/day × 5 days per cycle. Results: Twenty six of the 30 patients completed planned chemotherapy. Two patients experienced disease progression during therapy. There were no toxic deaths. One patient developed secondary leukemia. The 4-year event free survival (EFS) was 27% and the overall survival (OS) was 39%. Conclusions: Intensification of ifosfamide was tolerated and did not increase toxicity in patients with metastatic ES. The intensification did not improve outcomes for these patients with metastatic disease. Pediatr Blood Cancer 2015;62:594-597.

KW - Chemotherapy

KW - Ewing sarcoma

KW - Outcomes

UR - http://www.scopus.com/inward/record.url?scp=84923222093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923222093&partnerID=8YFLogxK

U2 - 10.1002/pbc.25373

DO - 10.1002/pbc.25373

M3 - Article

C2 - 25630954

AN - SCOPUS:84923222093

SN - 1545-5009

VL - 62

SP - 594

EP - 597

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 4

ER -

Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this